|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0026336,
umls-concept:C0035344,
umls-concept:C0078058,
umls-concept:C0185117,
umls-concept:C0231491,
umls-concept:C0249042,
umls-concept:C0302600,
umls-concept:C0392756,
umls-concept:C1256770,
umls-concept:C1420841,
umls-concept:C1522424,
umls-concept:C1700782,
umls-concept:C2003941,
umls-concept:C2698300,
umls-concept:C2911684
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-3-27
|
|
pubmed:abstractText |
To determine whether SB-267268, a nonpeptidic antagonist of the alpha(v)beta3 and alpha(v)beta5 integrins, attenuates angiogenesis in a murine model of retinopathy of prematurity (ROP) and alters the expression of vascular endothelial growth factor (VEGF) and its second receptor (VEGF-R2).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Benzazepines,
http://linkedlifedata.com/resource/pubmed/chemical/Integrin alphaVbeta3,
http://linkedlifedata.com/resource/pubmed/chemical/Integrins,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Vitronectin,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor...,
http://linkedlifedata.com/resource/pubmed/chemical/integrin alphaVbeta5,
http://linkedlifedata.com/resource/pubmed/chemical/vascular endothelial growth factor...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0146-0404
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1600-5
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16565398-Angiogenesis Inhibitors,
pubmed-meshheading:16565398-Animals,
pubmed-meshheading:16565398-Benzazepines,
pubmed-meshheading:16565398-Cell Adhesion,
pubmed-meshheading:16565398-Cell Movement,
pubmed-meshheading:16565398-Disease Models, Animal,
pubmed-meshheading:16565398-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:16565398-Female,
pubmed-meshheading:16565398-Gene Expression Regulation,
pubmed-meshheading:16565398-Humans,
pubmed-meshheading:16565398-Infant, Newborn,
pubmed-meshheading:16565398-Integrin alphaVbeta3,
pubmed-meshheading:16565398-Integrins,
pubmed-meshheading:16565398-Macaca,
pubmed-meshheading:16565398-Mice,
pubmed-meshheading:16565398-Mice, Inbred C57BL,
pubmed-meshheading:16565398-Pregnancy,
pubmed-meshheading:16565398-RNA, Messenger,
pubmed-meshheading:16565398-Rats,
pubmed-meshheading:16565398-Receptors, Vitronectin,
pubmed-meshheading:16565398-Retinal Neovascularization,
pubmed-meshheading:16565398-Retinopathy of Prematurity,
pubmed-meshheading:16565398-Vascular Endothelial Growth Factor A,
pubmed-meshheading:16565398-Vascular Endothelial Growth Factor Receptor-2
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
|
|
pubmed:affiliation |
Department of Physiology, University of Melbourne, Parkville, Victoria, Australia.jlaberka@unimelb.edu.au
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
